Back Back
ProCE Banner Activity

CME

CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer

Video

The introduction of CDK4/6 inhibitors into the treatment of HR-positive, HER2-negative metastatic breast cancer (mBC) resulted in a paradigm shift, and these agents are now considered the gold standard for first-line treatment. Since their approval, robust real-world data have been collected on the safety and efficacy of these agents outside the confines of a clinical trial. This includes new information on optimal selection between CDK4/6 inhibitors based on patient and disease characteristics and how best to sequence treatments across multiple lines of therapy.

This activity, CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer, will provide oncology practitioners with up-to-date information on the use of CDK4/6 inhibitors in the treatment of patients with HR-positive, HER2-negative mBC, including an in-depth evaluation of current clinical trial data and real-world experience with available CDK4/6 inhibitors and strategies for developing personalized patient treatment plans that take into consideration patient and disease characteristics such as comorbidities, menopausal status, and site of metastasis.

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: August 16, 2022

Expiration: August 16, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Megan Kruse

Megan Kruse, MD

Staff, Breast Medical Oncology, Cleveland Clinic
Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Ruth O'Regan

Ruth O'Regan, MD

Charles A. Dewey Endowed Professor of Medicine
Chair, Department of Medicine, University of Rochester Medical Center
Physician-in-Chief, Strong Memorial Hospital
Associate Director of Education and Mentoring, Wilmot Cancer Institute
Rochester, NY

Provided by

Jointly provided by the Potomac Center for Medical Education and Rockpointe

ProCE Banner
ProCE Banner

Supporters

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

The intended audience for this educational initiative is oncologists, nurses, and other clinicians involved in the management of patients with metastatic breast cancer.

Learning Objectives

At the conclusion of this education, participants should be able to:

  • Evaluate currently available CDK4/6 inhibitors for the treatment of HR+/HER2- metastatic breast cancer (mBC) based on clinical trial safety and efficacy data

  • Summarize outcomes of real-world studies and experiences with CDK4/6 inhibitors in HR+/HER2- mBC

  • Develop patient-personalized treatment plans for HR+/HER2- mBC that incorporate clinical trial and real-world evidence, treatment guidelines, and patient characteristics

Disclosure

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Primary Author

Megan Kruse, MD

Staff, Breast Medical Oncology, Cleveland Clinic
Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Megan Kruse, MD: Consulting Fee: Puma Biotechnology, Seagen, Lilly Oncology, Biotheranostics, Eisai, AstraZeneca, Gilead; Contracted Research: Lilly Oncology, Novartis Oncology, Tempus

Ruth O'Regan, MD

Charles A. Dewey Endowed Professor of Medicine
Chair, Department of Medicine, University of Rochester Medical Center
Physician-in-Chief, Strong Memorial Hospital
Associate Director of Education and Mentoring, Wilmot Cancer Institute
Rochester, NY

Ruth M. O'Regan, MD: Consulting Fee: Sanofi, Novartis, Pfizer, Genomic Health, Biotheranostics, Lilly, Puma Biotechnology, Genentech, Immunomedics, Macrogenics; Contracted Research: Novartis 

Planners and Managers

The planners and managers reported the following relevant financial relationships with ineligible companies:

Chelsey Goins, PhD: Has no relevant financial relationships

Content Reviewers

The content reviewers reported the following relevant financial relationships with ineligible companies:

Katie Propst, PhD: Has no relevant financial relationships

FDA DISCLOSURE
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Instructions for Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Accreditation

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN DESIGNATION CREDIT STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC credit or the evaluation, please email contact@potomacme.org.

ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
 
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. 

ABMS MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties ("ABMS") ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,  CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Family Medicine